I unmuted the television and listened to the next commercial break arrive. Another soft-lit couple. Another calm recital of catastrophic risks delivered over birdsong.
I wondered how many viewers would walk into appointments this week carrying a brand name they did not know last month. I wondered how many families with truly rare conditions were still fighting prior authorization while the awareness machine hummed.
We have built a healthcare system where miracles are real—and marketing is louder.
If we want the miracles to feel normal instead of luxurious, the solution is not silence. It is redesign.
Approve platforms once, not from scratch each time.
Pool risk so no insurer has an incentive to stall a cure.
Separate clinical education from revenue-dependent advertising.
Fund innovation transparently, and negotiate prices honestly.
Until then, the commercial break will continue doing clinical work.
And Sofia will keep sleeping through it.
Bibliography
1. Ventola, C. Lee. “Direct-to-Consumer Pharmaceutical Advertising: Therapeutic or Toxic?” Pharmacy and Therapeutics 36, no. 10 (2011): 669–684. Describes the United States and New Zealand as the only countries permitting full direct-to-consumer prescription drug advertising.
2. U.S. Food and Drug Administration. “Consumer-Directed Broadcast Advertisements; Draft Guidance.” Federal Register, August 12, 1997. Formalized how manufacturers could satisfy broadcast disclosure requirements for DTC television ads.
3. U.S. Government Accountability Office. Prescription Drugs: Medicare Spending on Drugs with Direct-to-Consumer Advertising . GAO-21-380, June 2021. Quantifies DTC advertising expenditures and concentration among brand-name drugs.
4. Kravitz, Richard L., et al. “Influence of Patients’ Requests for Direct-to-Consumer Advertised Antidepressants.” Journal of the American Medical Association 293, no. 16 (2005): 1995–2002. Randomized trial showing that patient requests significantly increase prescribing rates.
5. Molteni, Megan. “The Tricky Ethics of Big Pharma’s Soft Sell on Soap Operas.” Wired , May 2017. Reports on the General Hospital polycythemia vera storyline backed by Incyte.
6. Garde, Damian. “Drama and Diagnosis: Soap Opera Cancer Plotline Puts Incyte in Hot Seat.” FiercePharma , 2016. Describes oncologist criticism of the PV storyline as a marketing mechanism.
7. Robbins, Rebecca. “EpiPen’s Olympic Advertising Blitz.” STAT , August 2016. Details Mylan’s unbranded allergy awareness campaign during Olympic broadcasts.
8. DeAngelis, Christina. “Utah Jazz Rookie Opens Up About Heart Diagnosis in BMS Awareness Campaign.” FiercePharma , 2022. Covers Bristol Myers Squibb’s “Could It Be HCM?” unbranded awareness effort.
9. DeAngelis, Christina. “AZ’s Alexion Spotlights gMG in Awareness-Raising Film.” FiercePharma , 2023. Discusses Alexion’s documentary-style campaign around generalized myasthenia gravis.
10. U.S. Food and Drug Administration. “FDA Launches Crackdown on Deceptive Drug Advertising.” Press release, September 2025. Announces issuance of approximately 100 cease-and-desist notices and thousands of warning letters.
11. The White House. “Memorandum for the Secretary of Health and Human Services and the Commissioner of Food and Drugs.” September 2025. Directs federal agencies to ensure truthful and balanced DTC drug advertising.
12. Gardner Law Firm. “FDA Sends 100+ Cease-and-Desist Letters: A Warning to Industry on DTC Pharmaceutical Advertising.” 2025. Notes the sharp increase in enforcement compared to prior years.
13. Reuters. “U.S. FDA Chief Says Hims & Hers Super Bowl Ad Violated Drug Promotion Rules.” September 12, 2025. Reports regulatory concerns over Super Bowl weight-loss drug advertising.